Press Release Archives
Clearside Biomedical Inc
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which develops drug therapies to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina. The company was founded by Samirkumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Clearside Biomedical Inc Press Releases

Press Archives

Clearside Biomedical Inc

Press Archives

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

Oct 30th 2019

Clearside Biomedical to Present at the UBS Global Healthcare Conference

May 15th 2019

Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update

May 8th 2019

May 8, 2019 - Scientific Presentations Support Broad Applicability of Clearside Delivery Platform - - XIPERE™ under review for October 19, 2019

Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings

May 1st 2019

May 1, 2019 - SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery

Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019

Apr 25th 2019

April 25, 2019 ALPHARETTA, Ga., April 25, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing trea

Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings

Apr 18th 2019

Posters to be presented on gene therapy and visual acuity

Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO

Apr 8th 2019

April 8, 2019 ALPHARETTA, Ga., April 08, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treat

Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference

Apr 2nd 2019

April 2, 2019 ALPHARETTA, Ga., April 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treat

Clearside Biomedical Announces Fourth Quarter and Full Year 2018  Financial Results and Provides Corporate Update

Mar 12th 2019

Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Clearside Biomedical Announces Fourth Quar

Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference

Mar 4th 2019

March 4, 2019 ALPHARETTA, Ga., March 04, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treat

Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019

Feb 27th 2019

February 27, 2019 ALPHARETTA, Ga., Feb. 27, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing tr

Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019

Feb 20th 2019

February 20, 2019 ALPHARETTA, Ga., Feb. 20, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing tr